Cargando…

Spectrum of Immune Checkpoint Inhibitor Anemias: Results From a Single Center, Early-Phase Clinical Trials Case Series Experience

Immune checkpoint inhibitor anemias (ICI-A) are a rare entity which can be potentially life-threatening without prompt identification. The goal of the study is to characterize the presentation, evaluation, and outcomes of ICI therapy in early phase clinical trial setting to guide future research and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nelson, Blessie Elizabeth, Ejezie, Chinenye Lynette, Stephen, Bettzy A., Nardo, Mirella, Campbell, Erick, Gong, Jing, Hong, David S., Fu, Siqing, Yap, Timothy A., Murphy, Mariela Blum, Piha-Paul, Sarina, Daver, Naval G., Rojas-Hernandez, Cristhiam M., Naing, Aung
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elmer Press 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9275440/ https://www.ncbi.nlm.nih.gov/pubmed/35837373 http://dx.doi.org/10.14740/jh1006

Ejemplares similares

Revisiting Clinical Trials Using EGFR Inhibitor-Based Regimens in Patients with Advanced Non-Small Cell Lung Cancer: A Retrospective Analysis of an MD Anderson Cancer Center Phase I Population
por: Wheler, Jennifer, et al.
Publicado: (2013)

Pembrolizumab in vaginal and vulvar squamous cell carcinoma: a case series from a phase II basket trial
por: How, Jeffrey A., et al.
Publicado: (2021)

Safety and Efficacy of Immune Checkpoint Inhibitors in Patients with Cancer and Viral Hepatitis: The MD Anderson Cancer Center Experience
por: Nardo, Mirella, et al.
Publicado: (2023)

Adherence to the Recommended HPV Vaccine Dosing Schedule among Adolescents Aged 13 to 17 Years: Findings from the National Immunization Survey-Teen, 2019–2020
por: Ejezie, Chinenye Lynette, et al.
Publicado: (2022)

Development of a prognostic scoring system for patients with advanced cancer enrolled in immune checkpoint inhibitor phase 1 clinical trials
por: Sen, Shiraj, et al.
Publicado: (2018)

BRAF v600E–mutant cancers treated with vemurafenib alone or in combination with everolimus, sorafenib, or crizotinib or with paclitaxel and carboplatin (VEM-PLUS) study
por: Nelson, Blessie Elizabeth, et al.
Publicado: (2023)

Adult cancer-related hemophagocytic lymphohistiocytosis – a challenging diagnosis: a case report
por: Hust, Michael A., et al.
Publicado: (2017)

Parent-reported provider recommendation of HPV vaccination among minority adolescents before and during the COVID-19 pandemic: Findings from the National Immunization Survey-Teen, 2019–2021
por: Ejezie, Chinenye Lynette, et al.
Publicado: (2023)

The prevalence of human papillomavirus vaccination among racial and ethnic minority adolescents during the COVID-19 pandemic
por: Ejezie, Chinenye Lynette, et al.
Publicado: (2023)

Correction to: Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: results of a single‑center, multi‑arm phase Ib study
por: Thein, Kyaw Z., et al.
Publicado: (2021)

Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: Results of a single-center, multi-arm phase Ib study
por: Thein, Kyaw Z., et al.
Publicado: (2021)

Advanced gynecologic malignancies treated with a combination of the VEGF inhibitor bevacizumab and the mTOR inhibitor temsirolimus
por: Piha-Paul, Sarina A., et al.
Publicado: (2014)

Selinexor in Combination with Carboplatin and Pemetrexed in Patients with Advanced or Metastatic Solid Tumors: Results of an Open-Label, Single-Center, Multi-Arm Phase 1b Study
por: Thein, Kyaw Z., et al.
Publicado: (2022)

Hematologic complications of immune checkpoint inhibitors
por: Kroll, Michael H., et al.
Publicado: (2022)

Patient-reported symptom burden in patients with rare cancers receiving pembrolizumab in a phase II Clinical Trial
por: Mendoza, Tito R., et al.
Publicado: (2022)

P53 Mutations in Advanced Cancers: Clinical Characteristics, Outcomes, and Correlation between Progression-Free Survival and Bevacizumab-Containing Therapy
por: Said, Rabih, et al.
Publicado: (2013)

Dual EGFR inhibition in combination with anti-VEGF treatment in colorectal cancer
por: Falchook, Gerald S., et al.
Publicado: (2014)

Clinical characteristics and outcomes of phase I cancer patients with CCNE1 amplification: MD Anderson experiences
por: Yao, Shuyang, et al.
Publicado: (2022)

Dual EGFR inhibition in combination with anti-VEGF treatment: A phase I clinical trial in non-small cell lung cancer
por: Falchook, Gerald S., et al.
Publicado: (2013)

Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials
por: Groisberg, Roman, et al.
Publicado: (2017)

Evaluating the psychometric properties of the Immunotherapy module of the MD Anderson Symptom Inventory
por: Mendoza, Tito, et al.
Publicado: (2020)

T-cell receptor beta variable gene polymorphism predicts immune-related adverse events during checkpoint blockade immunotherapy
por: Stephen, Bettzy, et al.
Publicado: (2023)

Validation of prognostic scoring systems for patients with metastatic renal cell carcinoma enrolled in phase I clinical trials
por: Hahn, Andrew W, et al.
Publicado: (2020)

A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation
por: Piha-Paul, Sarina A., et al.
Publicado: (2023)

Exploring response signals and targets in aggressive unresectable hepatocellular carcinoma: an analysis of targeted therapy phase 1 trials
por: Subbiah, Ishwaria M., et al.
Publicado: (2015)

Long-term overall survival and prognostic score predicting survival: the IMPACT study in precision medicine
por: Tsimberidou, Apostolia-Maria, et al.
Publicado: (2019)

Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial
por: Subbiah, Vivek, et al.
Publicado: (2020)

Targeting Cancer Metabolism to Improve Outcomes with Immune Checkpoint Inhibitors
por: Fatima, Zainab, et al.
Publicado: (2023)

Efficacy of pembrolizumab in patients with advanced cancer of unknown primary (CUP): a phase 2 non-randomized clinical trial
por: Raghav, Kanwal P, et al.
Publicado: (2022)

Prevalence of MDM2 amplification and coalterations in 523 advanced cancer patients in the MD Anderson phase 1 clinic
por: Dembla, Vikas, et al.
Publicado: (2018)

Anastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway
por: Wheler, Jennifer J., et al.
Publicado: (2014)

Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus
por: Liu, Xiaochun, et al.
Publicado: (2016)

Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies
por: Wang, Yudong, et al.
Publicado: (2020)

Characteristics and outcomes for patients with advanced vaginal or vulvar cancer referred to a phase I clinical trials program: the MD Anderson cancer center experience
por: Fu, Siqing, et al.
Publicado: (2015)

Associations between the gut microbiome and fatigue in cancer patients
por: Hajjar, Joud, et al.
Publicado: (2021)

Phase 1 trial of ADI-PEG20 plus cisplatin in patients with pretreated metastatic melanoma or other advanced solid malignancies
por: Yao, Shuyang, et al.
Publicado: (2021)

Phase II Clinical Trial of Pembrolizumab in Patients with Progressive Metastatic Pheochromocytomas and Paragangliomas
por: Jimenez, Camilo, et al.
Publicado: (2020)

Venetoclax-Based Combinations in Acute Myeloid Leukemia: Current Evidence and Future Directions
por: Samra, Bachar, et al.
Publicado: (2020)

PIK3CA Mutations in Advanced Cancers: Characteristics and Outcomes
por: Janku, Filip, et al.
Publicado: (2012)

Selinexor in combination with standard chemotherapy in patients with advanced or metastatic solid tumors
por: Thein, Kyaw Z., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_sojtostht2cd0sicaki3qns0hg